According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell...
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell...
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
